➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Merck
Johnson and Johnson
Colorcon
Harvard Business School
Boehringer Ingelheim

Last Updated: November 24, 2020

DrugPatentWatch Database Preview

Litigation Details for Astellas Pharma Inc. v. Actavis Elizabeth LLC (D. Del. 2016)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Astellas Pharma Inc. v. Actavis Elizabeth LLC (D. Del. 2016)

Docket   Start Trial Date Filed 2016-10-06
Court District Court, D. Delaware Date Terminated 2020-10-05
Cause 35:271 Patent Infringement Assigned To Sue Lewis Robinson
Jury Demand None Referred To Christopher J. Burke
Parties PRINSTON PHARMACEUTICAL INC.
Patents 6,346,532; 6,562,375; 7,342,117; 7,982,049; 8,835,474; RE44,872
Attorneys Frederick L. Cottrell , III
Firms Young, Conaway, Stargatt & Taylor LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Astellas Pharma Inc. v. Actavis Elizabeth LLC
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for Astellas Pharma Inc. v. Actavis Elizabeth LLC (D. Del. 2016)

Date Filed Document No. Description Snippet Link To Document
2016-10-06 1 action for patent infringement of United States Patent Nos. 6,346,532 (“the ’532 patent”), 7,342,117…“Notification of Certification for U.S. Patent Nos. 6,346,532; 6,562,375; 7,342,117; 7,982,049; 8,835,4747,342,117 (“the ’117 patent”), 7,982,049 (“the ’049 patent”), 8,835,474 (“the ’474 patent”), and RE44,872 (“…validity and patentability of the ’532 patent. A true and correct copy of the ’532 patent is attached …(“the ’872 patent”), arising under the United States patent laws, Title 35, United States Code. This External link to document
2017-01-16 21 infringement of U.S. Patent Nos. 6,346,532 (“the ’532 patent”), 7,342,117 (“the ’117 patent”), 7,982,049 (…or more claim of U.S. Patent No. 6,346,532 (“the ’532 patent”) under the Patent Laws of the United States… to be a copy of United States Patent No. 6,346,532 (“the ’532 patent”), which indicates on its face … Paragraph IV certification as to U.S. Patent Nos. 6,346,532; 6,562,375; 7,342,117; 7,982,049; 8,835,474…“Notification of Certification for U.S. Patent Nos. 6,346,532; 6,562,375; 7,342,117; 7,982,049; 8,835,474 External link to document
2017-03-15 25 all purposes relating to United States Patent Nos. 6,346,532, 7,342,117, 7,982,049, 8,835,474, and RE44,872… certifications with respect to the 6,346,532 patent, and therefore have not been sued for …Paragraph III certifications with respect to the 6,346,532 patent, and therefore have not been sued for…Paragraph III certifications with respect to the 6,346,532 patent, and therefore have not been sued…Defendants. ) PATENT CASE SCHEDULING ORDER At Wilmington this External link to document
2017-04-24 33 Disclosures for Litigations Involving U.S. Patent Nos. 7,342,117, 7,982,049, 8,835,474 and RE44,872; and …Disclosures for Litigations Involving U.S. Patent Nos. 7,342,117, 7,982,049, 8,835,474 and RE44,872 filed…2016 5 October 2020 1:16-cv-00905 830 Patent None District Court, D. Delaware External link to document
2017-04-24 34 Disclosures for Litigations Involving U.S. Patent No. 6,346,532 and (2) Plaintiffs' Default Standard Disclosures…Disclosures for Litigations Involving U.S. Patent No. 6,346,532 filed by Astellas Ireland Co., Ltd., Astellas…2016 5 October 2020 1:16-cv-00905 830 Patent None District Court, D. Delaware External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
AstraZeneca
Moodys
Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.